Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC

Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.

There are no comments yet.

Please log in to write the first comment.